ARC1905
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for ARC1905, covering 2025-03-10 to 2025-03-10. Get the full timeline:
Most recent: Clinical Trial Update: ARC1905 (Anti-C5 Aptamer) Given With Lucentis 0.5 mg In People With Neovascular Age-Related Macular Degeneration [Phase 1]